News & Media
Press Center & More

Up-to-date press releases and statements in all categories, as well as materials for journalists.

May 13, 2022

Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan

May 9, 2022
Press release
Corporate and finance

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

May 6, 2022

Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years

Media contact

Email: [email protected]
Phone: (240) 720-7804

Images, videos, and files for media use

Extensive materials for members of the press, including broadcast, online, film, radio and print journalists.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.